TABLE OF CONTENTS

| ​ | Delaware                                                       | ​ | ​ | 58-2349413                              | ​ |
|---------|----------------------------------------------------------------|---------|---------|-----------------------------------------|---------|
| ​ | (State or other jurisdiction of incorporation or organization) | ​ | ​ | (I.R.S. Employer Identification Number) | ​ |
| ​ | 1010 Stony Hill Road Yardley, PA        | ​ | ​ |  19067 | ​ |
|---------|-----------------------------------------|---------|---------|--------------|---------|
| ​ | (Address of principal executive office) | ​ | ​ | (Zip Code)   | ​ |
| ​ | Title of each class            | ​ | ​ | Name of each exchange on which registered | ​ |
|---------|--------------------------------|---------|---------|-------------------------------------------|---------|
| ​ | Common Stock, $0.001 par value | ​ | ​ | The NASDAQ Stock Market LLC               | ​ |
| ​ | Large accelerated filer☐​   | ​ | ​ | Accelerated filer☐​               | ​ |
|---------|-----------------------------------------|---------|---------|-----------------------------------------------|---------|
| ​ | Non-accelerated filer☐​     | ​ | ​ | (Do not check if a smaller reporting company) | ​ |
| ​ | Smaller reporting company☑​ | ​ | ​ | Emerging growth company☐​         | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​

| ​ | PART III                                                                                                        | ​ | ​ |
|---------|-----------------------------------------------------------------------------------------------------------------|---------|---------|
| ​ | ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE ​                                          | ​ | ​ | ​ | ​ | 1 | ​ | ​ |
| ​ | ITEM 11.EXECUTIVE COMPENSATION  ​                                                                         | ​ | ​ | ​ | ​ | 5 | ​ | ​ |
| ​ | ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS  ​ | ​ | ​ | ​ | ​ | 14 | ​ | ​ |
| ​ | ITEM 13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE  ​                      | ​ | ​ | ​ | ​ | 18 | ​ | ​ |
| ​ | ITEM 14.PRINCIPAL ACCOUNTING FEES AND SERVICES  ​                                                         | ​ | ​ | ​ | ​ | 20 | ​ | ​ |
| ​ | PART IV                                                                                                         | ​ | ​ |
| ​ | ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES  ​                                                     | ​ | ​ | ​ | ​ | 21 | ​ | ​ |

----

TABLE OF CONTENTS​​

| Name               | ​ | ​ | Age | ​ | ​ | Position                                         | ​ |
|--------------------|---------|---------|-----|---------|---------|--------------------------------------------------|---------|
| David Johnson      | ​ | ​ | 60  | ​ | ​ | President, Chief Executive Officer and Director  | ​ |
| Joseph Warusz      | ​ | ​ | 61  | ​ | ​ | Chief Financial Officer, Treasurer and Secretary | ​ |
| Bradford Barton    | ​ | ​ | 57  | ​ | ​ | Chief Operating Officer                          | ​ |
| Pellegrino Pionati | ​ | ​ | 60  | ​ | ​ | Chief Strategy and Marketing Officer             | ​ |
| Joseph Leone       | ​ | ​ | 64  | ​ | ​ | Director                                         | ​ |
| Gary Restani       | ​ | ​ | 71  | ​ | ​ | Director                                         | ​ |
| Jeffrey Sklar      | ​ | ​ | 55  | ​ | ​ | Director                                         | ​ |
| Mark Wagner        | ​ | ​ | 61  | ​ | ​ | Director                                         | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​

| Name and Principal Position                                     | ​ | ​ | Year    | ​ | ​ | Salary  | ​ | ​ | Bonus   | ​ | ​ | Stock Awards(1) | ​ | ​ | Option Awards(1) | ​ | ​    | All Other Compensation | ​ | ​ | Total   | ​ |
|-----------------------------------------------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|-----------------|---------|---------|------------------|---------|------------|------------------------|---------|---------|---------|---------|
| David JohnsonPresident and Chief Executive Officer              | ​ | ​ | ​ | ​ | 2017    | ​ | ​ | ​ | ​ | $       | 350,000 | ​         | ​ | ​ | ​          | $       | 276,500(3) | ​                | ​ | ​ | ​ | $       | 274,000 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 11,400(5) | ​ | ​ | ​ | ​ | $ | 911,900 | ​ | ​ |
| ​                                                         | ​ | ​ | 2016    | ​ | ​ | ​ | ​ | $       | 350,000 | ​ | ​ | ​         | ​ | $       | 245,000(4)       | ​ | ​    | ​                | ​ | $       | 258,000 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 11,400(5) | ​ | ​ | ​ | ​ | $ | 864,400 | ​ | ​ |
| Brian Posner(2)Chief Financial Officer, Treasurer and Secretary | ​ | ​ | ​ | ​ | 2017    | ​ | ​ | ​ | ​ | $       | 246,800 | ​         | ​ | ​ | ​          | $       | 118,310(8) | ​                | ​ | ​ | ​ | $       | 103,829 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 8,400(6) | ​ | ​ | ​ | ​ | $ | 477,339 | ​ | ​ |
| ​                                                         | ​ | ​ | 2016    | ​ | ​ | ​ | ​ | $       | 240,000 | ​ | ​ | ​         | ​ | $       | 100,800(4)       | ​ | ​    | ​                | ​ | $       | 86,000  | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 8,400(6) | ​ | ​ | ​ | ​ | $ | 435,200 | ​ | ​ |
| Bradford Barton Chief Operating Officer                         | ​ | ​ | ​ | ​ | 2017    | ​ | ​ | ​ | ​ | $       | 246,800 | ​         | ​ | ​ | ​          | $       | 118,310(3) | ​                | ​ | ​ | ​ | $       | 103,829 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 8,400(7) | ​ | ​ | ​ | ​ | $ | 477,339 | ​ | ​ |
| ​                                                         | ​ | ​ | 2016    | ​ | ​ | ​ | ​ | $       | 240,000 | ​ | ​ | ​         | ​ | $       | 100,800(4)       | ​ | ​    | ​                | ​ | $       | 86,000  | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 8,400(7) | ​ | ​ | ​ | ​ | $ | 435,200 | ​ | ​ |
| Pellegrino PionatiChief Strategy and Marketing Officer          | ​ | ​ | ​ | ​ | 2017    | ​ | ​ | ​ | ​ | $       | 246,800 | ​         | ​ | ​ | ​          | $       | 118,310(3) | ​                | ​ | ​ | ​ | $       | 103,829 | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 8,400(6) | ​ | ​ | ​ | ​ | $ | 477,339 | ​ | ​ |
| ​                                                         | ​ | ​ | 2016    | ​ | ​ | ​ | ​ | $       | 240,000 | ​ | ​ | ​         | ​ | $       | 100,800(4)       | ​ | ​    | ​                | ​ | $       | 86,000  | ​ | ​ | ​ | ​ | $ | — | ​ | ​ | ​ | ​ | $ | 8,400(6) | ​ | ​ | ​ | ​ | $ | 435,200 | ​ | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​       | ​ | ​ | Option Awards                                                   | ​ | ​ | Stock Awards                                                      | ​ |
|---------------|---------|---------|-----------------------------------------------------------------|---------|---------|-------------------------------------------------------------------|---------|
| Name          | ​ | ​ | Number of Securities Underlying Unexercised Options Exercisable | ​ | ​ | Number of Securities Underlying Unexercised Options Unexercisable | ​ | ​ | Option Exercise Price | ​ | ​ | Option Expiration Date | ​ | ​ | Number of Shares or Units of Stock That Have Not Vested | ​ | ​ | Market Value of Shares or Units of Stock That Have Not Vested | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | 5,920   | ​                                                           | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 43.80 | ​ | ​ | ​ | ​ | ​ | 11/29/22 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | 5,920   | ​                                                           | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 65.60 | ​ | ​ | ​ | ​ | ​ | 11/29/22 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | 5,920   | ​                                                           | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 87.50 | ​ | ​ | ​ | ​ | ​ | 11/29/22 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | 27,923  | ​                                                           | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 32.80 | ​ | ​ | ​ | ​ | ​ | 02/04/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | 11,713  | ​                                                           | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 35.00 | ​ | ​ | ​ | ​ | ​ | 11/14/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | 73,058  | ​                                                           | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 68.20 | ​ | ​ | ​ | ​ | ​ | 12/20/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | 7,668   | ​                                                           | ​ | ​ | ​ | ​ | 3,834(1) | ​ | ​ | ​ | ​ | $ | 62.30 | ​ | ​ | ​ | ​ | ​ | 02/06/25 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | ​ | ​                                                           | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,000(2) | ​ | ​ | ​ | ​ | $ | 18,100(3) | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | ​ | ​                                                           | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 30,000(4) | ​ | ​ | ​ | ​ | $ | 54,300(3) | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | ​ | ​                                                           | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 50,000(5) | ​ | ​ | ​ | ​ | $ | 90,500(3) | ​ | ​ |
| David Johnson | ​ | ​ | ​                                                         | ​ | ​ | ​                                                           | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 30,000(6) | ​ | ​ | ​ | ​ | $ | 54,300(3) | ​ | ​ |

----

TABLE OF CONTENTS

| ​            | ​ | ​ | Option Awards                                              | ​ | ​ | Stock Awards                                                 | ​ |
|--------------------|---------|---------|------------------------------------------------------------|---------|---------|--------------------------------------------------------------|---------|
| Name               | ​ | ​ | Number ofSecuritiesUnderlyingUnexercisedOptionsExercisable | ​ | ​ | Number ofSecuritiesUnderlyingUnexercisedOptionsUnexercisable | ​ | ​ | OptionExercisePrice | ​ | ​ | OptionExpirationDate | ​ | ​ | Number ofShares orUnits ofStock ThatHave NotVested | ​ | ​ | MarketValue ofShares orUnits ofStock ThatHave NotVested | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | 6,172   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 43.80 | ​ | ​ | ​ | ​ | ​ | 09/03/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | 6,172   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 65.60 | ​ | ​ | ​ | ​ | ​ | 09/03/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | 6,172   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 87.50 | ​ | ​ | ​ | ​ | ​ | 09/03/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | 7,002   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 90.00 | ​ | ​ | ​ | ​ | ​ | 03/06/24 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | 7,668   | ​                                                      | ​ | ​ | ​ | ​ | 3,834(1) | ​ | ​ | ​ | ​ | $ | 62.30 | ​ | ​ | ​ | ​ | ​ | 02/06/25 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3,334(2) | ​ | ​ | ​ | ​ | $ | 6,035(3) | ​ | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,002(4) | ​ | ​ | ​ | ​ | $ | 18,104(3) | ​ | ​ |
| Brian Posner       | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,000(6) | ​ | ​ | ​ | ​ | $ | 18,100(3) | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | 5,487   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 43.80 | ​ | ​ | ​ | ​ | ​ | 05/10/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | 5,487   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 54.70 | ​ | ​ | ​ | ​ | ​ | 05/10/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | 5,487   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 65.60 | ​ | ​ | ​ | ​ | ​ | 05/10/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | 5,487   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 87.50 | ​ | ​ | ​ | ​ | ​ | 05/10/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | 5,487   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 109.40 | ​ | ​ | ​ | ​ | ​ | 05/10/23 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | 7,002   | ​                                                      | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | $ | 90.00 | ​ | ​ | ​ | ​ | ​ | 03/06/24 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | 7,668   | ​                                                      | ​ | ​ | ​ | ​ | 3,834(1) | ​ | ​ | ​ | ​ | $ | 62.30 | ​ | ​ | ​ | ​ | ​ | 02/06/25 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3,334(2) | ​ | ​ | ​ | ​ | $ | 6,035(3) | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,002(4) | ​ | ​ | ​ | ​ | $ | 18,104(3) | ​ | ​ |
| Bradford Barton    | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,000(6) | ​ | ​ | ​ | ​ | $ | 18,100(3) | ​ | ​ |
| Pellegrino Pionati | ​ | ​ | ​                                                    | ​ | 6,668   | ​                                                      | ​ | ​ | ​ | ​ | 3,334(7) | ​ | ​ | ​ | ​ | $ | 52.50 | ​ | ​ | ​ | ​ | ​ | 06/15/25 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Pellegrino Pionati | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3,000(7) | ​ | ​ | ​ | ​ | $ | 5,430(3) | ​ | ​ |
| Pellegrino Pionati | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,002(4) | ​ | ​ | ​ | ​ | $ | 18,104(3) | ​ | ​ |
| Pellegrino Pionati | ​ | ​ | ​                                                    | ​ | ​ | ​                                                      | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,000(6) | ​ | ​ | ​ | ​ | $ | 18,100(3) | ​ | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​                       | ​ | ​ | Year    | ​ | ​ | Fees Earned or Paid in Cash | ​ | ​ | Option Awards(1) | ​ | ​    | Total   | ​ |
|-------------------------------|---------|---------|---------|---------|---------|-----------------------------|---------|---------|------------------|---------|------------|---------|---------|
| Jerome Zeldis, M.D., Ph.D.(2) | ​ | ​ | ​ | ​ | 2017    | ​                     | ​ | ​ | ​          | $       | 30,000     | ​ | ​ | ​ | ​ | $ | 22,318(3) | ​ | ​ | ​ | ​ | $ | 52,318 | ​ | ​ |
| Winston Kung(4)               | ​ | ​ | ​ | ​ | 2017    | ​                     | ​ | ​ | ​          | $       | —(5) | ​ | ​ | ​ | ​ | $ | —(6) | ​ | ​ | ​ | ​ | $ | — | ​ | ​ |
| Joseph Leone                  | ​ | ​ | ​ | ​ | 2017    | ​                     | ​ | ​ | ​          | $       | 28,125     | ​ | ​ | ​ | ​ | $ | 22,318(3) | ​ | ​ | ​ | ​ | $ | 50,443 | ​ | ​ |
| Gary Restani                  | ​ | ​ | ​ | ​ | 2017    | ​                     | ​ | ​ | ​          | $       | 27,189     | ​ | ​ | ​ | ​ | $ | 22,318(3) | ​ | ​ | ​ | ​ | $ | 49,507 | ​ | ​ |
| Jeffrey Sklar                 | ​ | ​ | ​ | ​ | 2017    | ​                     | ​ | ​ | ​          | $       | 28,750     | ​ | ​ | ​ | ​ | $ | 22,318(3) | ​ | ​ | ​ | ​ | $ | 51,068 | ​ | ​ |
| Mark Wagner                   | ​ | ​ | ​ | ​ | 2017    | ​                     | ​ | ​ | ​          | $       | 18,750     | ​ | ​ | ​ | ​ | $ | 22,318(3) | ​ | ​ | ​ | ​ | $ | 41,068 | ​ | ​ |

----

TABLE OF CONTENTS​

| ​                                                    | ​ | ​ | Number of securities to be issued upon exercise of outstanding | ​ | ​    | Weighted average exercise price of outstanding options | ​ | ​ | Number of securities remaining available for future issuance | ​ |
|------------------------------------------------------------|---------|---------|----------------------------------------------------------------|---------|------------|--------------------------------------------------------|---------|---------|--------------------------------------------------------------|---------|
| Equity compensation plans approved by security holders     | ​ | ​ | ​                                                        | ​ | 561,152    | ​                                                | ​ | ​ | ​                                                      | $       | 25.93 | ​ | ​ | ​ | ​ | ​ | 123,362 | ​ | ​ |
| Equity compensation plans not approved by security holders | ​ | ​ | ​                                                        | ​ | 285,852(1) | ​                                                | ​ | ​ | ​                                                      | $       | 63.05 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Total                                                      | ​ | ​ | ​                                                        | ​ | 847,004    | ​                                                | ​ | ​ | ​                                                      | $       | 38.46 | ​ | ​ | ​ | ​ | ​ | 123,362 | ​ | ​ |
| ​                                                    |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| Name of Beneficial Owner                                                | ​ | ​ | Number of Shares Beneficially Owned(1) | ​ | ​    | Percentage Beneficially Owned(1) | ​ |
|-------------------------------------------------------------------------|---------|---------|----------------------------------------|---------|------------|----------------------------------|---------|
| 5% Owners                                                               | ​ | ​ | ​                                | ​ | ​    | ​                          | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901           | ​ | ​ | ​                                | ​ | 902,519(2) | ​                          | ​ | ​ | ​ | ​ | 17.7% | ​ | ​ |
| Perceptive Advisors, LLC 499 Park Avenue, 25th Floor New York, NY 10022 | ​ | ​ | ​                                | ​ | 643,730(3) | ​                          | ​ | ​ | ​ | ​ | 12.3% | ​ | ​ |
| Officers and Directors                                                  | ​ | ​ | ​                                | ​ | ​    | ​                          | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| David I. Johnson                                                        | ​ | ​ | ​                                | ​ | 282,814(4) | ​                          | ​ | ​ | ​ | ​ | 5.5% | ​ | ​ |
| Joseph Warusz                                                           | ​ | ​ | ​                                | ​ | —    | ​                          | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Brian M. Posner(12)                                                     | ​ | ​ | ​                                | ​ | 64,656(5)  | ​                          | ​ | ​ | ​ | ​ | 1.3% | ​ | ​ |
| Bradford C. Barton                                                      | ​ | ​ | ​                                | ​ | 82,798(6)  | ​                          | ​ | ​ | ​ | ​ | 1.6% | ​ | ​ |
| Pellegrino Pionati                                                      | ​ | ​ | ​                                | ​ | 40,660(7)  | ​                          | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Joseph M. Leone                                                         | ​ | ​ | ​                                | ​ | 21,194(8)  | ​                          | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Jeffrey Sklar                                                           | ​ | ​ | ​                                | ​ | 18,805(9)  | ​                          | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Gary Restani                                                            | ​ | ​ | ​                                | ​ | 15,700(10) | ​                          | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mark Wagner                                                             | ​ | ​ | ​                                | ​ | 54,430(11) | ​                          | ​ | ​ | ​ | ​ | 1.1% | ​ | ​ |
| Directors and executive officers as a group (9 persons)                 | ​ | ​ | ​                                | ​ | 581,057    | ​                          | ​ | ​ | ​ | ​ | 11.0% | ​ | ​ |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​

| ​            | ​ | ​ | Year Ended December 31, 2017 | ​ | ​ | Year Ended December 31, 2016 | ​ |
|--------------------|---------|---------|-----------------------------------|---------|---------|-----------------------------------|---------|
| Audit fees         | ​ | ​ | ​                           | $       | 219,081 | ​                           | ​ | ​ | ​ | $ | 203,425 | ​ | ​ |
| Audit-related fees | ​ | ​ | ​                           | ​ | 61,896  | ​                           | ​ | ​ | ​ | ​ | 29,165 | ​ | ​ |
| Tax fees           | ​ | ​ | ​                           | ​ | — | ​                           | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Total              | ​ | ​ | ​                           | $       | 281,077 | ​                           | ​ | ​ | ​ | $ | 232,590 | ​ | ​ |
| ​            |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS

| ​ | ​ | ​ | ​ | ALLIQUA BIOMEDICAL, INC. | ​ |
|---------|---------|---------|---------|--------------------------|---------|
| ​ | ​ | ​ | ​ | By:                      | ​ | ​ | /s/ DAVID JOHNSON​David Johnson President and Chief Executive Officer | ​ |
| Signature                             | ​ | ​ | Title                                                                                         | ​ | ​ | Date                | ​ |
|---------------------------------------|---------|---------|-----------------------------------------------------------------------------------------------|---------|---------|---------------------|---------|
| /s/ DAVID JOHNSON​David Johnson | ​ | ​ | President, Chief Executive Officer and Director (principal executive officer)                 | ​ | ​ | April 30, 2018 | ​ |
| /s/ JOSEPH WARUSZ​Joseph Warusz | ​ | ​ | Chief Financial Officer, Treasurer and Secretary (principal financial and accounting officer) | ​ | ​ | April 30, 2018 | ​ |
| /s/ JOSEPH LEONE​Joseph Leone   | ​ | ​ | Director                                                                                      | ​ | ​ | April 30, 2018 | ​ |
| /s/ GARY RESTANI​Gary Restani   | ​ | ​ | Director                                                                                      | ​ | ​ | April 30, 2018 | ​ |
| /s/ JEFFREY SKLAR​Jeffrey Sklar | ​ | ​ | Director                                                                                      | ​ | ​ | April 30, 2018 | ​ |
| /s/ MARK WAGNER​Mark Wagner     | ​ | ​ | Director                                                                                      | ​ | ​ | April 30, 2018 | ​ |

----

TABLE OF CONTENTS

| Exhibit No. | ​ | ​ | Description                                                                                                                                                                                                                                                                                                                        | ​ |
|------------------|---------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 2.1              | ​ | ​ | Agreement and Plan of Merger, dated May 5, 2014, by and between Alliqua, Inc., ALQA Merger Sub, Inc., Choice Therapeutics, Inc. and E. James Hutchens, as the Stockholder Representative, incorporated by reference to Exhibit 2.1 to the Form 8-K filed May 6, 2014.                                               | ​ |
| 2.2              | ​ | ​ | Agreement and Plan of Merger, dated June 5, 2014, by and between Alliqua, Inc. and Alliqua BioMedical, Inc., incorporated by reference to Exhibit 2.1 to the Form 8-K filed June 11, 2014.                                                                                                                          | ​ |
| 2.3**            | ​ | ​ | Agreement and Plan of Merger, dated February 2, 2015, by and among Alliqua BioMedical, Inc., ALQA Cedar, Inc., Celleration, Inc. and certain representatives of the stockholders of Celleration, Inc., as identified therein, incorporated by reference to Exhibit 2.1 to the Form 8-K filed February 2, 2015. | ​ |
| 2.4**            | ​ | ​ | Contribution Agreement and Plan of Merger, dated October 5, 2016, by and among Alliqua BioMedical, Inc., Alliqua Holdings, Inc., Chesapeake Merger Corp., and Soluble Systems, LLC, incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on October 6, 2016.                            | ​ |
| 2.5**            | ​ | ​ | Asset Purchase Agreement, dated January 5, 2018, by and between Alliqua BioMedical, Inc. and Celularity Inc., incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on January 5, 2018.                                                                                             | ​ |
| 2.6**            | ​ | ​ | Asset Purchase Agreement, dated August 31, 2017, by and between Alliqua BioMedical, Inc. and Argentum Medical, LLC, incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on September 5, 2017.                                                                                          | ​ |
| 3.1              | ​ | ​ | Certificate of Incorporation of Alliqua BioMedical, Inc., incorporated by reference to Exhibit 3.1 to the Form 8-K filed June 11, 2014.                                                                                                                                                                                  | ​ |
| 3.2              | ​ | ​ | Certificate of Amendment to Certificate of Incorporation of Alliqua BioMedical, Inc., incorporated by reference to Exhibit 3.3 to the Form 8-K filed June 11, 2014.                                                                                                                                                      | ​ |
| 3.3              | ​ | ​ | Certificate of Amendment to Certificate of Incorporation of Alliqua BioMedical, Inc., incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 6, 2016.                                                                                                                                   | ​ |
| 3.4              | ​ | ​ | Certificate of Amendment to Certificate of Incorporation of Alliqua BioMedical, Inc., incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on October 5, 2017.                                                                                                                               | ​ |
| 3.5              | ​ | ​ | Bylaws of Alliqua BioMedical, Inc., incorporated by reference to Exhibit 3.2 to the Form 8-K filed June 11, 2014.                                                                                                                                                                                                        | ​ |
| 4.1              | ​ | ​ | Form of Warrant used in connection with February 16, 2012 private placement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed February 21, 2012.                                                                                                                                                     | ​ |
| 4.2              | ​ | ​ | Form of Warrant used in connection with August 14, 2012 private placement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed August 16, 2012.                                                                                                                                                         | ​ |
| 4.3              | ​ | ​ | Form of Warrant used in connection with November 8, 2012 private placement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed November 14, 2012.                                                                                                                                                      | ​ |
| 4.4              | ​ | ​ | Form of Warrant used in connection with February 22, 2013 private placement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed February 25, 2013.                                                                                                                                                     | ​ |
| 4.5              | ​ | ​ | Form of Warrant used in connection with April and May 2013 private placement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed April 26, 2013.                                                                                                                                                       | ​ |
| 4.6              | ​ | ​ | Form of Warrant used in connection with June 28, 2013 private placement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed July 5, 2013.                                                                                                                                                              | ​ |

----

TABLE OF CONTENTS

| Exhibit No. | ​ | ​ | Description                                                                                                                                                                                                                                       | ​ |
|------------------|---------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 4.7              | ​ | ​ | Form of  $0.10 Warrant used in connection with October 22, 2013 private placement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed October 28, 2013.                                                         | ​ |
| 4.8              | ​ | ​ | Warrant issued to Celgene Corporation on November 18, 2013, incorporated by reference to Exhibit 4.12 to the Form 10-K filed December 31, 2013.                                                                                    | ​ |
| 4.9              | ​ | ​ | Form of Warrant used in connection with November 18, 2013 private placement, incorporated by reference to Exhibit 4.13 to the Form 10-K filed December 31, 2013.                                                                   | ​ |
| 4.10             | ​ | ​ | Form of Warrant, dated April 14, 2014, by and between Alliqua, Inc. and certain accredited investors, incorporated by reference to Exhibit 10.2 to the Form 8-K filed April 15, 2014.                                              | ​ |
| 4.11             | ​ | ​ | Form of Warrant, dated April 3, 2017, by and between Alliqua BioMedical, Inc. and H.C. Wainwright & Co. LLC and its designees, incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed April 4, 2017. | ​ |
| 10.1+            | ​ | ​ | 2001 Incentive Stock Purchase Plan, incorporated by reference to Exhibit 10.2 to the Form S-8 filed on May 8, 2003.                                                                                                                | ​ |
| 10.2+            | ​ | ​ | Form of Nonstatutory Stock Option Agreement under the 2001 Incentive Stock Purchase Plan, incorporated by reference to Exhibit 10.2 to the Form 10-K/A filed May 16, 2013.                                                              | ​ |
| 10.3+            | ​ | ​ | Form of Incentive Stock Option Agreement under the 2001 Incentive Stock Purchase Plan, incorporated by reference to Exhibit 10.3 to the Form 10-K/A filed May 16, 2013.                                                                 | ​ |
| 10.4+            | ​ | ​ | Form of Indemnification Agreement, incorporated by reference to Exhibit 10.2 to the Form 8-K filed January 5, 2011.                                                                                                                | ​ |
| 10.5             | ​ | ​ | Exclusive License Agreement, dated as of July 15, 2011, by and between Noble Fiber Technologies, LLC and Alliqua Biomedical, Inc., incorporated by reference to Exhibit 10.1 to the Form 8-K filed July 20, 2011.                  | ​ |
| 10.6             | ​ | ​ | Collateral Assignment of 510(k) Rights, dated as of July 15, 2011, by and between Noble Fiber Technologies, LLC and Alliqua Biomedical, Inc., incorporated by reference to Exhibit 10.1 to the Form 8-K filed July 20, 2011.       | ​ |
| 10.7+            | ​ | ​ | 2011 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 to the Form 8-K filed December 20, 2011.                                                                                                                       | ​ |
| 10.8             | ​ | ​ | Form of Securities Purchase Agreement, by and among Alliqua, Inc. and certain purchasers set forth therein, incorporated by reference to Exhibit 10.1 to the Form 8-K filed February 21, 2012.                                          | ​ |
| 10.9             | ​ | ​ | Securities Purchase Agreement, dated as of August 14, 2012, by and among Alliqua, Inc. and certain purchasers set forth therein, incorporated by reference to Exhibit 10.1 to the Form 8-K filed August 16, 2012.             | ​ |
| 10.10            | ​ | ​ | Securities Purchase Agreement, dated as of November 8, 2012, by and among Alliqua, Inc. and certain purchasers set forth therein, incorporated by reference to Exhibit 10.1 to the Form 8-K filed November 14, 2012.               | ​ |
| 10.11+           | ​ | ​ | First Amendment to the 2011 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 to the Form 8-K filed December 20, 2012.                                                                                                | ​ |
| 10.12+           | ​ | ​ | Form of Nonstatutory Stock Option Agreement under the 2011 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.32 to the Form 10-K/A filed May 16, 2013.                                                                  | ​ |
| 10.13+           | ​ | ​ | Form of Incentive Stock Option Agreement under the 2011 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.33 to the Form 10-K/A filed May 16, 2013.                                                                     | ​ |
| 10.14+           | ​ | ​ | Executive Employment Agreement, dated as of February 4, 2013, between Alliqua, Inc. and David Johnson, incorporated by reference to Exhibit 10.1 to the Form 8-K filed February 7, 2013.                                           | ​ |

----

TABLE OF CONTENTS

| Exhibit No. | ​ | ​ | Description                                                                                                                                                                                                                                              | ​ |
|------------------|---------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 10.15+           | ​ | ​ | Indemnification Agreement, dated as of February 4, 2013, in favor of David Johnson, incorporated by reference to Exhibit 10.3 to the Form 8-K filed February 7, 2013.                                                                     | ​ |
| 10.16            | ​ | ​ | Securities Purchase Agreement, dated as of February 22, 2013, by and among Alliqua, Inc. and certain purchasers set forth therein, incorporated by reference to Exhibit 10.1 to the Form 8-K filed February 25, 2013.                     | ​ |
| 10.17            | ​ | ​ | Securities Purchase Agreement, dated as of April 11, 2013, by and among Alliqua, Inc. and certain purchasers set forth therein, incorporated by reference to Exhibit 10.1 to the Form 8-K filed April 26, 2013.                      | ​ |
| 10.18            | ​ | ​ | Securities Purchase Agreement, dated as of June 28, 2013, by and among Alliqua, Inc. and certain purchasers set forth therein, incorporated by reference to Exhibit 10.3 to the Form 8-K filed July 5, 2013.                         | ​ |
| 10.19+           | ​ | ​ | Nonqualified Stock Option Agreement, dated September 3, 2013, between Brian Posner and Alliqua, Inc., incorporated by reference to Exhibit 10.2 to the Form 8-K filed September 9, 2013.                                                  | ​ |
| 10.20^           | ​ | ​ | Distributor Agreement, dated September 23, 2013, by and between Sorbion GmbH & Co KG and Alliqua Biomedical, Inc., incorporated by reference to Exhibit 10.5 to the Form 10-Q filed November 12, 2013.                                | ​ |
| 10.21^           | ​ | ​ | License, Marketing and Development Agreement, dated as of November 14, 2013, by and between Anthrogenesis Corporation, d/b/a CCT, and Alliqua, Inc., incorporated by reference to Exhibit 10.48 to the Form 10-K filed December 31, 2013. | ​ |
| 10.22^           | ​ | ​ | Supply Agreement, dated as of November 14, 2013, by and between Anthrogenesis Corporation and Alliqua, Inc., incorporated by reference to Exhibit 10.49 to the Form 10-K filed December 31, 2013.                                         | ​ |
| 10.23            | ​ | ​ | Stock Purchase Agreement, dated as of November 14, 2013, by and between Celgene Corporation and Alliqua, Inc., incorporated by reference to Exhibit 10.50 to the Form 10-K filed December 31, 2013.                                       | ​ |
| 10.24            | ​ | ​ | Securities Purchase Agreement, dated as of November 18, 2013, by and among Alliqua, Inc. and certain purchasers set forth therein, incorporated by reference to Exhibit 10.51 to the Form 10-K filed December 31, 2013.                   | ​ |
| 10.25            | ​ | ​ | First Amendment to Executive Employment Agreement dated December 20, 2013, by and between Alliqua, Inc. and David Johnson, incorporated by reference to Exhibit 10.1 to the Form 8-K filed December 27, 2013.                             | ​ |
| 10.26            | ​ | ​ | Nonqualified Stock Option Agreement dated December 20, 2013, by and between Alliqua, Inc. and David Johnson, incorporated by reference to Exhibit 10.2 to the Form 8-K filed December 27, 2013.                                           | ​ |
| 10.27+           | ​ | ​ | Form of Restricted Stock Award Agreement under the 2011 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.62 to the Form 10-K filed December 31, 2013.                                                                         | ​ |
| 10.28+           | ​ | ​ | Form of Restricted Stock Award Agreement for 2013 Executive Bonuses under the 2011 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.63 to the Form 10-K filed December 31, 2013.                                              | ​ |
| 10.29+           | ​ | ​ | Form of Nonqualified Stock Option Agreement (outside of any incentive plan), incorporated by reference to Exhibit 99.8 to the Form S-8 filed January 23, 2014.                                                                                 | ​ |
| 10.30            | ​ | ​ | Form of Securities Purchase Agreement, dated April 14, 2014, by and between Alliqua, Inc. and certain accredited investors, incorporated by reference to Exhibit 10.1 to the Form 8-K filed April 15, 2014.                               | ​ |

----

TABLE OF CONTENTS

| Exhibit No. | ​ | ​ | Description                                                                                                                                                                                                                                                                                                                                                                | ​ |
|------------------|---------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 10.31            | ​ | ​ | Form of Letter Agreement, dated April 11, 2014, by and between Alliqua, Inc. and certain holders of warrants to purchase Common Stock of Alliqua, Inc., incorporated by reference to Exhibit 10.3 to the Form 8-K filed April 15, 2014.                                                                                                                     | ​ |
| 10.32+           | ​ | ​ | Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 to the Form 8-K filed June 11, 2014.                                                                                                                                                                                                                           | ​ |
| 10.33^           | ​ | ​ | Supply Agreement, dated April 10, 2014, by and between Alliqua, Inc. and Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics, incorporated by reference to Exhibit 10.4 to the Form 10-Q filed August 11, 2014.                                                                                                                                  | ​ |
| 10.34^           | ​ | ​ | First Amendment to Supply Agreement, dated April 10, 2014 by and between Alliqua, Inc. and Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics, incorporated by reference to Exhibit 10.5 to the Form 10-Q filed August 11, 2014.                                                                                                                | ​ |
| 10.35^           | ​ | ​ | First Amendment to License, Marketing and Development Agreement, dated September 30, 2014, by and between Alliqua, Inc. and Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics, incorporated by reference to Exhibit 10.1 to the Form 10-Q filed November 5, 2014.                                                                              | ​ |
| 10.36^           | ​ | ​ | Second Amendment to Supply Agreement, dated September 30, 2014, by and between Alliqua, Inc. and Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics, incorporated by reference to Exhibit 10.2 to the Form 10-Q filed November 5, 2014.                                                                                                         | ​ |
| 10.37            | ​ | ​ | Voting Agreement, dated February 2, 2015, by and between Alliqua BioMedical, Inc. and each of the stockholders of Celleration, Inc., as identified therein, incorporated by reference to Exhibit 10.1 to Amendment No. 1 to Registration Statement on Form S-4 filed on April 2, 2015.                                                                      | ​ |
| 10.38            | ​ | ​ | Commitment Letter, dated February 2, 2015, by and between Perceptive Credit Opportunities Fund, LP and Alliqua BioMedical, Inc., incorporated by reference to Exhibit 10.2 to Amendment No. 1 to Registration Statement on Form S-4 filed on April 2, 2015.                                                                                                 | ​ |
| 10.39            | ​ | ​ | Side Letter Agreement to Commitment Letter, dated March 10, 2015, by and between Perceptive Credit Opportunities Fund, LP and Alliqua BioMedical, Inc., incorporated by reference to Exhibit 10.3 to Amendment No. 1 to Registration Statement on Form S-4 filed on April 2, 2015.                                                                          | ​ |
| 10.40^           | ​ | ​ | Second Amendment to the License, Marketing and Development Agreement, dated April 30, 2015, by and between Alliqua BioMedical, Inc. and Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics, incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2015. | ​ |
| 10.41+           | ​ | ​ | First Amendment to the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 6, 2015.                                                                                                                                     | ​ |
| 10.42+           | ​ | ​ | Form of Incentive Stock Option Agreement under the 2014 Long-Term Incentive Plan, incorporated by reference to Exhibit 99.3 to the Form S-8 filed August 6, 2015.                                                                                                                                                                                                | ​ |
| 10.43+           | ​ | ​ | Form of Nonqualified Stock Option Agreement under the 2014 Long-Term Incentive Plan, incorporated by reference to Exhibit 99.4 to the Form S-8 filed August 6, 2015.                                                                                                                                                                                             | ​ |
| 10.44+           | ​ | ​ | Form of Restricted Stock Award Agreement under the 2014 Long-Term Incentive Plan, incorporated by reference to Exhibit 99.5 to the Form S-8 filed August 6, 2015.                                                                                                                                                                                                | ​ |
| 10.45+           | ​ | ​ | Form of Restricted Stock Unit Agreement under the 2014 Long-Term Incentive Plan, incorporated by reference to Exhibit 99.6 to the Form S-8 filed August 6, 2015.                                                                                                                                                                                                 | ​ |

----

TABLE OF CONTENTS

| Exhibit No. | ​ | ​ | Description                                                                                                                                                                                                                                                                                                                                                | ​ |
|------------------|---------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 10.46            | ​ | ​ | Credit Agreement and Guaranty, dated May 29, 2015, by and among Alliqua BioMedical, Inc., Perceptive Credit Opportunities Fund, LP and those certain subsidiary guarantors party thereto, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 1, 2015.    | ​ |
| 10.47            | ​ | ​ | Pledge and Security Agreement, dated May 29, 2015, by and among Alliqua BioMedical, Inc., Perceptive Credit Opportunities Fund, LP and those certain subsidiary guarantor party thereto, incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 1, 2015.     | ​ |
| 10.48            | ​ | ​ | Warrant, dated May 29, 2015, by and between Alliqua BioMedical, Inc. and Perceptive Credit Opportunities Fund, LP, incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 1, 2015.                                                                           | ​ |
| 10.49+           | ​ | ​ | Employment Agreement, dated June 3, 2015, by and between Alliqua BioMedical, Inc. and Nino Pionati, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2015.                                                                                          | ​ |
| 10.50+           | ​ | ​ | Employment Agreement, dated June 5, 2015, by and between Alliqua BioMedical, Inc. and Brian Posner, incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2015                                                                                           | ​ |
| 10.51+           | ​ | ​ | Employment Agreement, dated June 5, 2015, by and between Alliqua BioMedical, Inc. and Bradford Barton, incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2015.                                                                                  | ​ |
| 10.52            | ​ | ​ | First Amendment to Distributor Agreement, dated July 31, 2015, by and between Alliqua BioMedical, Inc. and BSN Medical, Inc., an affiliate of Sorbion GmbK & Co KG, incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2015.               | ​ |
| 10.53            | ​ | ​ | Purchase Agreement, dated June 30, 2016, by and between Alliqua BioMedical, Inc. and BSN medical, Inc., incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2016.                                                                            | ​ |
| 10.54            | ​ | ​ | Transition Agreement, dated June 30, 2016, by and between Alliqua BioMedical, Inc. and BSN medical, Inc., incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2016.                                                                               | ​ |
| 10.55            | ​ | ​ | Consent Agreement, dated August 25, 2016, by and among Alliqua BioMedical, Inc., certain subsidiaries set forth on the signature pages thereto, and Perceptive Credit Holdings, L.P., incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2016. | ​ |
| 10.56            | ​ | ​ | Forbearance and Amendment Agreement, dated January 26, 2017, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 30, 2017.                      | ​ |
| 10.57            | ​ | ​ | Amended Warrant, dated January 26, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP., incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 30, 2017.                                                                    | ​ |
| 10.58            | ​ | ​ | Form of Securities Purchase Agreement, dated February 27, 2017, by and between Alliqua BioMedical, Inc. and certain accredited investors, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 28, 2017.                                               | ​ |

----

TABLE OF CONTENTS

| Exhibit No. | ​ | ​ | Description                                                                                                                                                                                                                                                                                                                                         | ​ |
|------------------|---------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 10.59            | ​ | ​ | Amendment No. 1 to Forbearance and Amendment Agreement, dated March 7, 2017, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 13, 2017. | ​ |
| 10.60            | ​ | ​ | Amended Warrant, dated March 7, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP., incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 13, 2017.                                                                  | ​ |
| 10.61            | ​ | ​ | Amended Warrant, dated April 6, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 12, 2017.                                                                  | ​ |
| 10.62            | ​ | ​ | Amendment No. 2 to Forbearance and Amendment Agreement, dated April 27, 2017, by and among Alliqua BioMedical, Inc. AquaMed Technologies and Perceptive Credit Holdings, LP., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 1, 2017           | ​ |
| 10.63            | ​ | ​ | Amendment to Credit Agreement and Guaranty and Warrant, dated June 1, 2017, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, L.P., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 5, 2017    | ​ |
| 10.64+           | ​ | ​ | Second Amendment to the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan, effective as of June 23, 2017, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2017                                                                        | ​ |
| 10.65            | ​ | ​ | Second Forbearance Agreement, dated August 9, 2017, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 10, 2017                          | ​ |
| 10.66            | ​ | ​ | Consent, Forbearance and Amendment Agreement, dated August 31, 2017, by and among Alliqua BioMedical, Inc. AquaMed Technologies, Inc. and Perceptive Credit Holdings, L.P., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 5, 2017       | ​ |
| 10.67            | ​ | ​ | Forbearance and Amendment Agreement, dated February 5, 2018, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, L.P., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 9, 2018               | ​ |
| 10.68            | ​ | ​ | Amendment Agreement, dated March 13, 2018, by and among by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, L.P., incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 15, 2018                      | ​ |
| 10.69            | ​ | ​ | Bridge Loan Note, dated March 13, 2018, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, L.P., incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 15, 2018                                                                | ​ |
| 10.70            | ​ | ​ | General Release and Severance Agreement, dated as of March 15, 2018, by and between Brian Posner and Alliqua BioMedical, Inc., incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 15, 2018                                                       | ​ |
| 21.1∞      | ​ | ​ | List of Subsidiaries                                                                                                                                                                                                                                                                                                                                | ​ |
| 23.1∞      | ​ | ​ | Consent of Independent Registered Public Accounting Firm to the Form 10-K.                                                                                                                                                                                                                                                                          | ​ |

----

TABLE OF CONTENTS

| Exhibit No. | ​ | ​ | Description                                                                                                                                                                                                                                                                                                                                                                                                                                    | ​ |
|------------------|---------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 31.1*            | ​ | ​ | Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                                                                                            | ​ |
| 31.2*            | ​ | ​ | Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                                                                                            | ​ |
| 32.1∞      | ​ | ​ | Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                       | ​ |
| 32.2∞      | ​ | ​ | Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                       | ​ |
| 101∞       | ​ | ​ | The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, formatted in XBRL (eXtensible Business Reporting Language), (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders’ Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements | ​ |

----